{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:52:47Z","timestamp":1794671567019,"version":"4.9.1"},"reference-count":67,"publisher":"American Chemical Society (ACS)","issue":"10","license":[{"start":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:00:00Z","timestamp":1757203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","award":["955756"],"award-info":[{"award-number":["955756"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol. Pharmaceutics"],"published-print":{"date-parts":[[2025,10,6]]},"DOI":"10.1021\/acs.molpharmaceut.5c00755","type":"journal-article","created":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T13:48:28Z","timestamp":1757252908000},"page":"6067-6082","source":"Crossref","is-referenced-by-count":3,"title":["Canine Mdr1 Knockout MDCK Cells Reliably Estimate Human Small Intestinal Permeability (<i>P<\/i><sub>eff<\/sub>) and Fraction Absorbed (<i>f<\/i><sub>a<\/sub>)"],"prefix":"10.1021","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7918-0865","authenticated-orcid":true,"given":"Kristian","family":"Beran","sequence":"first","affiliation":[{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology","place":["Frankfurt am Main, Germany"]},{"name":"Johnson & Johnson, Pharmaceutical & Material Sciences","place":["Beerse, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Hee","family":"Park","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Translational PK\/PD & Investigational Toxicology","place":["Spring House, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Van den Bergh","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Translational PK\/PD & Investigational Toxicology","place":["Beerse, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dressman","sequence":"additional","affiliation":[{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology","place":["Frankfurt am Main, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline","family":"Hermans","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Pharmaceutical & Material Sciences","place":["Beerse, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4894-7765","authenticated-orcid":true,"given":"Ren\u00e9","family":"Holm","sequence":"additional","affiliation":[{"name":"University of Southern Denmark","place":["Odense, Denmark"]},{"name":"Department of Physics, Chemistry and Pharmacy","place":["Odense, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Lin","sequence":"additional","affiliation":[{"name":"Medpace","place":["Cincinnati, United States"]},{"name":"Bioanalytical Laboratory","place":["Cincinnati, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kia","family":"Sepassi","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Discovery Pharmaceutics","place":["San Diego, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Bioanalytical Discovery & Development Sciences","place":["Spring House, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Evers","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Translational PK\/PD & Investigational Toxicology","place":["Spring House, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2025,9,7]]},"reference":[{"key":"ref1\/cit1","unstructured":"International Council for Harmonisation\nof Technical Requirements for Pharmaceuticals for Human Use (ICH) Biopharmaceutics classification system-based\nbiowaivers M9.  ICH Harmonised Guideline. https:\/\/www.ich.org\/page\/multidisciplinary-guidelines (accessed\nApril 11, 2024)."},{"key":"ref2\/cit2","unstructured":"Food and Drug Administration\n(FDA). Scale-Up and Postapproval Changes:\nChemistry, Manufacturing, and Controls, In Vitro Dissolution Testing,\nand In Vivo Bioequivalence Documentation; 1995."},{"key":"ref3\/cit3","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016212804288"},{"key":"ref4\/cit4","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.04.016"},{"key":"ref5\/cit5","unstructured":"Food and Drug Administration\n(FDA). Guidance for Industry. Waiver\nof in Vivo Bioavailability and Bioequivalence Studies for Immediate-Release\nSolid Oral Dosage Forms Based on a Biopharmaceutics Classification\nSystem; 2000."},{"key":"ref6\/cit6","doi-asserted-by":"publisher","DOI":"10.1002\/jps.22217"},{"key":"ref7\/cit7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2018.03.030"},{"key":"ref8\/cit8","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2018.10.044"},{"key":"ref9\/cit9","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15102397"},{"key":"ref10\/cit10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.106098"},{"issue":"1","key":"ref11\/cit11","first-page":"75","volume":"7","author":"Sun D.","year":"2004","journal-title":"Curr. Opin Drug Discov. Devel."},{"key":"ref12\/cit12","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.4c00202"},{"key":"ref13\/cit13","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.4c00526"},{"key":"ref14\/cit14","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015888813741"},{"key":"ref15\/cit15","doi-asserted-by":"publisher","DOI":"10.1021\/js970332a"},{"key":"ref16\/cit16","unstructured":"Dahlgren, D. Animal-based methods to study permeability. Presentation held online at  APV Workshop on The Role of Permeability in Oral Drug Development, 22 November 2022; 2022."},{"key":"ref17\/cit17","unstructured":"Dressman, J. The Future of Permeability Testing. Presentation held at  M-CERSI, 6 December 2021; 2021."},{"key":"ref18\/cit18","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2072"},{"key":"ref19\/cit19","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.11.149"},{"key":"ref20\/cit20","doi-asserted-by":"publisher","DOI":"10.1021\/mp2004912"},{"key":"ref21\/cit21","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2024.09.022"},{"key":"ref22\/cit22","doi-asserted-by":"publisher","DOI":"10.1021\/jm901846t"},{"key":"ref23\/cit23","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24258"},{"key":"ref24\/cit24","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020483911355"},{"key":"ref25\/cit25","unstructured":"Tchaparian, E, Tang, L, Xu, G, Huang, T, Jin, L. Cell Based Experimental Models as Tools for the Prediction of Human Intestinal Absorption.  15th North American ISSX Meeting, San Diego; 2008."},{"key":"ref26\/cit26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1993.tb05691.x"},{"key":"ref27\/cit27","doi-asserted-by":"publisher","DOI":"10.3109\/10611869509015945"},{"key":"ref28\/cit28","unstructured":"Food and Drug\nAdministration\n(FDA). Product Quality Review(s).\nApplication Number: 212327Orig1s000. INREBIC (fedratinib) Capsules. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm (accessed\n24 September 2024)."},{"key":"ref29\/cit29","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3549(15)00171-9"},{"key":"ref30\/cit30","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.8b00688"},{"key":"ref31\/cit31","doi-asserted-by":"publisher","DOI":"10.1177\/026119291003800510"},{"key":"ref32\/cit32","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016065715308"},{"key":"ref33\/cit33","doi-asserted-by":"publisher","DOI":"10.1016\/S1093-3263(02)00163-8"},{"key":"ref34\/cit34","doi-asserted-by":"publisher","DOI":"10.1080\/00498250701704819"},{"key":"ref35\/cit35","doi-asserted-by":"publisher","DOI":"10.1021\/mp800145r"},{"key":"ref36\/cit36","doi-asserted-by":"publisher","DOI":"10.1021\/jm901371v"},{"key":"ref37\/cit37","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90145-9"},{"key":"ref38\/cit38","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011020025338"},{"key":"ref39\/cit39","doi-asserted-by":"publisher","DOI":"10.1016\/S0928-0987(02)00005-2"},{"key":"ref40\/cit40","doi-asserted-by":"publisher","DOI":"10.1021\/jm9810102"},{"key":"ref41\/cit41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1990.tb05384.x"},{"key":"ref42\/cit42","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012134219095"},{"key":"ref43\/cit43","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5173(95)04204-0"},{"key":"ref44\/cit44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2013.08.025"},{"key":"ref45\/cit45","unstructured":"Pfizer, Inc. Highlights of Prescribing Information, VFEND\u00ae\n(voriconazole)\ntablets, for oral use. https:\/\/www.pfizermedicalinformation.com\/en-us\/vfend."},{"key":"ref46\/cit46","unstructured":"European\nMedicines Agency (EMA). Inrebic: EPAR\u2500Public\nassessment report.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/inrebic."},{"key":"ref47\/cit47","unstructured":"Food\nand Drug Administration\n(FDA). Multi-Discipline Review. Inrebic\n(fedratinib)\u2500Application Number: 212327Orig1s000. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm (accessed 24 September 2024)."},{"key":"ref48\/cit48","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.120.000229"},{"key":"ref49\/cit49","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12606"},{"key":"ref50\/cit50","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1683"},{"key":"ref51\/cit51","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00423-11"},{"key":"ref52\/cit52","unstructured":"Food and Drug Administration\n(FDA). Product Quality Review(s).\nApplication Number 213137 Orig1s000. Oxbryta (Voxelotor) Tablets. Available at: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm. Accessed 24 September 2024."},{"key":"ref53\/cit53","unstructured":"Kyowa Kirin Inc. Prescribing information, NOURIANZ\u00ae (istradefylline)\ntablets, for oral use. Available at: https:\/\/www.nourianzhcp.com\/ Accessed 24 September 2024."},{"key":"ref54\/cit54","unstructured":"Food and Drug Administration\n(FDA). Product Quality Review(s),\nNourianz\u00ae (istradefylline) tablets. Application Number: 022075Orig1s000. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/022075Orig1s000TOC.cfm."},{"key":"ref55\/cit55","unstructured":"European\nMedicines Agency (EMA). Oxbryta: EPAR\n- Public Assessment Report. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/oxbryta."},{"key":"ref56\/cit56","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2020.09.039"},{"key":"ref57\/cit57","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2007.303"},{"key":"ref58\/cit58","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1986.tb04501.x"},{"key":"ref59\/cit59","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2121-12-43"},{"key":"ref60\/cit60","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.3c00108"},{"key":"ref61\/cit61","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics4020314"},{"key":"ref62\/cit62","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-020-02964-z"},{"key":"ref63\/cit63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189521"},{"key":"ref64\/cit64","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.8b00416"},{"key":"ref65\/cit65","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20392"},{"key":"ref66\/cit66","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018961805118"},{"key":"ref67\/cit67","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2015.10.030"}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.5c00755","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.5c00755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T08:11:10Z","timestamp":1759738270000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/doi\/10.1021\/acs.molpharmaceut.5c00755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,7]]},"references-count":67,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,6]]}},"alternative-id":["10.1021\/acs.molpharmaceut.5c00755"],"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5c00755","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5c00755.s001","asserted-by":"subject"}]},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,7]]}}}